Key Results and Lives Saved

Since our inception in 2002, health programs supported by the Global Fund partnership have saved 70 million lives.

Key Results

The coverage of key treatment and prevention interventions for HIV, TB and malaria in countries where the Global Fund invests has increased significantly since our founding. In 2024, 79% of people living with HIV were on antiretroviral therapy, up from 22% in 2010. TB treatment coverage reached 75% in 2023 – its highest-ever level – up from 45% in 2010. The percentage of the population with access to a long-lasting insecticide-treated net reached 61% in 2023 – its highest level to date – up from 29% in 2010.

The results achieved last year once again demonstrate the strength of the Global Fund model, and underscore why investing in this unique partnership is one of the most effective ways to save lives, improve the health of those living in the poorest communities and reinforce global health security. 

We measure our progress against the targets in the global plans for HIV, TB and malaria and in the Sustainable Development Goal (SDG) 3 of health and well-being for all. Our achievements are the result of efforts by a wide array of actors comprising the Global Fund partnership, including governments, multilateral agencies, bilateral partners, the private sector, civil society groups, and people and communities affected by the three diseases.

In 2024, the Global Fund joined partners in a commitment to reach 2 million people with lenacapavir, a breakthrough in HIV prevention. A twice-yearly, long-acting injectable pre-exposure prophylaxis (PrEP) option, lenacapavir showed up to 100% success in preventing new HIV infections in clinical trials and offers unprecedented potential to improve adherence, increase uptake of PrEP and maximize return on investment. 

The Global Fund also invests in other HIV prevention options – including condoms, lubricants, and harm reduction products that reduce the risk of HIV infection among people who inject drugs – to ensure that people at highest risk have access to effective tools and the knowledge to protect themselves.

Smart, sustained investment to fight HIV will continue to deliver exceptional returns – reducing new infections and deaths, easing pressure on health systems and strengthening global health security. As more countries integrate HIV services into primary care, they are laying the foundation for resilient, people-centered systems that will outlast support from external sources. 

HIV Infections Among Adolescent Girls and Young Women

In 2024, an estimated 210,000 adolescent girls and young women (aged 15-24) acquired HIV globally, compared to 160,000 boys and men of the same age. This disparity underscores how gender inequality, limited access to education and health care, discrimination and gender-based violence continue to drive new infections and create barriers to prevention, treatment and support.

Yet new infections among adolescent girls and young women have declined significantly in recent years, due to the scale-up of HIV testing and treatment and expanded access to prevention tools, education and community-led initiatives. In 2024, 2 million adolescent girls and young women in Global Fund-supported countries accessed HIV prevention services.

Reduction in HIV incidence rate among women aged 15-24

Participants register to be tested for HIV at a “mobile session” at a coffee shop in Vinh City, Vietnam. Organized by the Glink Clinic, these mobile sessions inform people about the clinic and its services, as well as offer HIV testing and access to PrEP. The Global Fund/Quinn Ryan Mattingly

Investing for Impact

The Global Fund provides 26% of all international financing for HIV programs. Since the Global Fund was founded in 2002, we have invested US$27.6 billion in HIV programs and US$8.6 billion in HIV/TB programs as of 30 June 2025. Global Fund investments to tackle HIV not only drive progress against the disease, but also contribute to building strong and resilient health and community systems that are able to confront other emerging health threats.

Progress Towards the Global Targets

Working with partners, the Global Fund has supported many countries to reach the UNAIDS 95-95-95 targets – where 95% of people living with HIV know their status, 95% of those who know their status are on treatment and 95% of those on treatment achieve viral suppression. Seven countries where the Global Fund invests have already achieved the targets: Botswana, Eswatini, Lesotho, Namibia, Rwanda, Zambia and Zimbabwe. Eight sub-Saharan African countries have reached 90% on each of the three targets. This level of progress is clear evidence that controlling the HIV epidemic is within reach when the right tools and resources are in place. 

People living with HIV on antiretroviral therapy
In countries where the Global Fund invests

Source: UNAIDS 2025 release data. People on antiretroviral therapy reported to UNAIDS in countries supported by the Global Fund over the past two funding cycles. Programmatic results published in other parts of this report are based primarily on data reported to the Global Fund in 2024, according to the grant reporting cycle.

Download data (CSV format)

With robust funding commitments, bold leadership and full use of the tools now at hand, we can take the next decisive step to end AIDS – and build a healthier future for all.

Screening and testing continued, and efforts to find undiagnosed people with TB – a key element of a successful fight against the disease – expanded. A game-changing scale-up of innovative tools and approaches in the countries most affected by TB has led to more people being successfully diagnosed, treated and cured of the disease.

Cutting-edge tools such as AI-powered computer-aided detection software and digital portable chest X-rays are revolutionizing TB screening. The Global Fund has invested over US$193 million over the 2021-2025 period to roll out AI-enabled TB screening in more than 20 countries. AI is not only a tool that can help us beat TB, but also a platform that can power a much more efficient use of resources, support integrated service delivery, and strengthen pandemic preparedness. 

But together, we can choose to change the trajectory of this fight. Investing in TB now is not just about saving lives – it’s also an opportunity to protect decades of progress, strengthen health systems, and build a more resilient, equitable future. With the right mix of domestic commitment, smart financing and global solidarity, we can choose to end TB as a public health threat and unlock broader advancements in health and development. 

Trends in TB Burden

Working with governments, the private sector, health workers, civil society and communities, the Global Fund partnership has reduced TB deaths by 40% between 2002 and 2023. Without these efforts, TB deaths would have increased by 134% and TB cases by 40% over the same period. The tuberculosis mortality rate has reduced by 57% since 2002, and the incidence rate has declined by 28%.  

Investing for Impact

The Global Fund provides 73% of all international financing for TB. Since 2002, we have invested US$10.5 billion in programs to prevent and treat TB and an additional US$8.6 billion in TB/HIV programs as of 30 June 2025. To protect the success the Global Fund partnership has achieved over the last two decades, we are optimizing existing resources and tools to maximize the impact of every dollar.

Nzombi Ngoma was forced to stop working as a general laborer after experiencing TB symptoms. He has been on TB treatment for the last four months, but he had to be admitted to the Pediatric Foundation of Kimbondo Hospital in Kinshasa, Democratic Republic of the Congo, due to complications. With continued treatment he is expected to make a full recovery. Global Fund/Vincent Becker

Progress Towards the Global Targets

To accelerate progress on preventing TB infections and deaths, we are working on an exciting pipeline of innovative tools, including near-point-of-care tests, which can increase access to timely TB diagnosis, better treatments and a broader range of preventive tools. There are at least five TB vaccines in phase III efficacy trials, and work is underway to develop next-generation vaccines based on mRNA and other promising platforms. The Global Fund is part of the Tuberculosis Vaccine Accelerator Council and aims to play a key role in supporting countries to integrate the new TB vaccine into their TB prevention strategies.

TB treatment coverage
In countries where the Global Fund invests

TB treatment coverage can be approximated as the annual number of people newly diagnosed with TB and officially reported as a TB case divided by the estimated number of people who developed TB (incident cases) in the same year, expressed as a percentage. The data is from the WHO Global Tuberculosis Report 2024, in countries supported by the Global Fund over the past two funding cycles. Programmatic results published in other parts of this report are based primarily on data reported to the Global Fund in 2024.

Download data (CSV format)

Robust funding commitments in 2025 are absolutely critical to maintaining our momentum against TB and preventing a resurgence that could undo decades of hard-won progress.

Driven by the leadership of affected communities and partner countries, Global Fund-supported malaria programs prioritize sustainability and empower local solutions that build long-term resilience. This approach not only accelerates progress in the fight against malaria, but also strengthens health and community systems to better withstand future threats. 

Trends in Malaria Burden

In countries where we invest, malaria deaths have been reduced by 29% between 2002 and 2023, even though the population in these countries has increased by 46%. Without malaria control measures, deaths would have increased by 94% over the same period. Between 2002 and 2023, malaria cases in countries supported by the Global Fund increased by 8%. Without malaria control measures, cases would have increased by 81% over the same period.

Investing for Impact

The Global Fund provides 59% of all international financing for malaria programs and has invested more than US$20.3 billion in malaria programs as of June 2025. Investing in malaria programs not only reduces the burden of this deadly disease, but also helps make the world better prepared for other health threats, strengthening global health security. Enhancing real-time surveillance systems improves essential health system infrastructure, enabling communities and countries to detect outbreaks early and respond to emerging pandemics. These surveillance systems help identify drivers of malaria transmission in real-time and enable health authorities to implement targeted and impactful interventions.

Members of a spray team prepare their equipment before spraying homes with insecticide to protect families from malaria in Kaukira, Honduras. The Global Fund/Tommy Trenchard/Rooftop

As proved by Suriname and Timor-Leste – both certified malaria-free by WHO in 2025 – the target of ending malaria is within reach. But we must work even harder to regain lost progress and ensure that crises such as conflict and climate change do not derail our efforts.

Progress Towards the Global Targets

Thanks to sustained global efforts, countries have made significant strides in reducing malaria incidence and deaths. 

The population in sub-Saharan Africa has grown significantly over the past two decades, resulting in a larger number of people living in areas at high risk of malaria infection. Despite this, malaria programs supported by the Global Fund have drastically increased the percentage of population coverage with insecticide-treated nets, from 4% in 2002 to 61% in 2023. As a result, the absolute number of people protected from malaria has increased substantially – from 23 million in 2002 to 692 million in 2023 in sub-Saharan Africa. This expanded protection has contributed to a 51% reduction in the malaria mortality rate since 2002, along with a 26% decline in the incidence rate in countries supported by the Global Fund. 

People with access to an insecticide-treated mosquito net
In sub-Saharan African countries where the Global Fund invests

Source: WHO/Malaria Atlas Project estimates 2024 (38 African countries for which data is available).

Download data (CSV format)

Any reduction in commitment now would allow diseases like malaria to resurge with devastating force, endangering the most vulnerable and threatening the entire global population and global stability.